Clinical Trials · NCT01278342

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Name: Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Octreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 70
Start date: Sep 2006
Locations: 20 sites, 5 countries
Primary endpoint: The Percentage of Participants With Complete Response (CR) at 8 Months

View Octreotide compound reference